Clinical Trial Update: A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02 [Phase 2]

View source ↗

Summary

A Phase 2 continuation trial for subjects with systemic lupus erythematosus who completed a prior protocol (LBSL02) has completed, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Snippet

Sponsor: Human Genome Sciences Inc., a GSK Company | Conditions: Systemic Lupus Erythematosus | Phase 2 | Status: COMPLETED | Results posted: 2017-04-28